ViraCorp’s Partnership with Lancaster University

In UK Baker Botts LLP, advised on the matter.

Baker Botts LLP advised Viracorp with a team including David Ramm (Picture – Corporate M&A).

ViraCorp, a British biomedical firm, announced a partnership with Lancaster University to develop a unique nasal COVID-19 vaccine which attacks the virus at its entry point into the body.

Under its subsidiary ViraVac, ViraCorp’s new vaccine is based on the work of Lancaster Molecular Virologist Dr Muhammad Munir, a pioneer of needleless and next-generation COVID-19 vaccines. The ViraVac vaccine will provide a cost-effective and easily administered alternative to solutions currently on the market.

The Viravac vaccine is an intranasal vaccine, which induces a special type of antibodies in the respiratory tract as the first line of defense against the virus. It is hoped that the nasal method will improve the pace of the global vaccine rollout, as well as remove the need for extensive training that is required for delivering vaccines via intramuscular injections.

The Baker Botts team was led by David Ramm (Picture) and Sonia Namutebi.

Involved fees earner: Sonia Namutebi – Baker Botts LLP; David Ramm – Baker Botts LLP;

Law Firms: Baker Botts LLP;

Clients: Viracorp;

Author: Giulia Di Palma